GLP-1 RAs are associated with a modestly increased risk for GERD and gallstone disease but not with GI and biliary complications.

Would you get a one-time genetic modification such that you'd never have to take a GLP-1 drug for weight loss ever again?

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

Denmark: Following a recent World Health Organization (WHO) alert on semaglutide-containing medicines, Novo Nordisk has ...

Tweaking your daily routine so you move more, drink enough water, and sleep better are all helpful adjustments for anyone ...

The high dose of Wegovy is one part of Novo Nordisk's plan to defend its obesity business, along with a major ...

An updated edition of the June 4, 2025 article. The world is in the midst of a historic demographic shift with populations ...

ESSENCE trial of Novo Nordisk's GLP-1 drug semaglutide shows efficacy in MASH, setting up filings in the US and Europe next year.

Top-Line Data Expected in the Fourth Quarter of 2025 CAMBRIDGE, Mass., July 9, 2025 /PRNewswire/ -- MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology ...

Armed with the latest biological knowledge and cutting-edge computational techniques—and, of course, investor dollars—these ...

Weight loss jabs like Mounjaro may aid obesity treatment, but skipping crucial blood tests can trigger severe side ...